go-v.orgdoi

Historical perspective and advances in the treatment of multiple myeloma

Amir Harandi, Damian A. Laber · Oncology Reviews · 2011

  • DOI 10.4081/133
  • Publisher PAGEPress (Italy)
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Oncology Reviews · PAGEPress (Italy) · article · 2011

Abstract

Corticosteroids and melphalan were used for decades to treat multiple myeloma. Combination chemotherapy has been extensively studied with similar overall survival rates to melphalan and prednisone. In the last decade, the development of new agents has progressed significantly. Thalidomide and its newer derivatives lenalidomide, bortezomib, and pegylated liposomal doxorubicin have drastically revolutionized treatment approaches. As a result, numerous clinical trials have yielded exciting treatment strategies resulting in therapeutic advances, and improved responses and overall survival of patients.

This review summarizes the international uniform response criteria for multiple myeloma and gives a historical perspective on previous therapies with updates on the newest available treatments.

Open the resolved locator · 10.4081/133

Metadata licence: OpenAlex metadata (CC0)